The Chin Is In! New First In Class Injectable Treatment for ‘Double Chin’ is Now Available in Canada

Text size:

TORONTO, March 23, 2016 /CNW/ – Facial aesthetic treatments to date have been focused on wrinkles, discolouration, volume loss and lines that appear on the face.  However, for the first time, new advancements in injectable aesthetic treatments are broadening this scope by targeting problem areas below the chin that typically have been difficult to treat due to stubborn fat. The ‘double chin’ that has plagued both men and women of all shapes and sizes has finally met its match, thanks to this new innovative treatment.

BELKYRATM (deoxycholic acid injection) is the first and only Health Canada approved non-surgical injectable treatment specifically designed to improve the appearance of moderate to severe amounts of fat under the chin – commonly known as “double chin” in adults.i BELKYRA™ is deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into fat under the chin, BELKYRA™ can cause the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat any longer.ii

“For patients with double chin, many are unaware that it is a treatable condition. Until now treatments have typically included surgery, handheld devices or aggressive weight-loss regimens with potentially limited improvement,” says Dr. Vince Bertucci, dermatologist, President of the Canadian Dermatology Association and BELKYRATM trial investigator. “BELKYRA’s approval is part of a growing trend in medical aesthetic science.  More than ever before, we now have innovative, minimally invasive treatments with results that in the past would be achievable only with surgery.”

Fullness under the chin is a common, yet under-treated aesthetic condition that can impact both women and meniii.  Double chin is often resistant to diet and exercise alone and is generally caused by several factors such as aging, genetics and weight gainiv. Simply put, a double chin may be part of a person’s DNA.

A new approach to a common problem
“As a person ages they can experience a diminishment of their ‘persona’ and of the face they present to the world,” says Dr Lisa Kellett, a top dermatologist from DLK on Avenue and past president of the Canadian Laser and Aesthetic Specialists Society (CLASS).  “There’s often a mismatch between the person they feel they are on the inside, versus the persona they project out into the world.  Treatments that soften signs of aging or restore chin contours and profile can have a significant, positive impact on a person’s self-esteem.”

The shape of the face and chin profile area can influence how a person is viewed by others and how a person feels about themselves.v  So it’s no surprise that according to a survey conducted by the American Society for Dermatologic Surgery (ASDS), over 67 per cent of consumers surveyed reported being bothered by fullness under the chinvi. For both men and women, a double chin can lead to a negative self-impression – even among younger adult patients.vii 

“BELKYRA™’s availability in Canada is an important milestone for Allergan,” said Kevin O’Brien of Allergan Canada. “With BELKYRA™ joining BOTOX Cosmetic®, the JUVÉDERM® line of products, and LATISSE® we now have one of the most comprehensive medical aesthetics offerings in the industry.  With this robust portfolio we can better enable medical aesthetic physicians to take a holistic approach to treating the whole face.”

In clinical studies on adults with moderate to severe fullness under the chin, 79 per cent of people treated with BELKYRATM reported improved satisfaction with the appearance of the area beneath their chin 12 weeks after their last treatmentviii. After being treated with BELKYRATM, patients also reported improvement in self-perception, including feeling happier and younger, based on their chin profile, as well as feeling less embarrassed, less self-conscious, less overweight, and less bothered by submental fullnessix.

Each in-office treatment session is typically 15-20 minutes and many people experience visible results in two to four treatment sessions spaced at least one month apart depending on the desired results. Up to six treatments may be given.x Your medical aesthetic physician will help you determine how many treatment sessions you need based on the amount and distribution of your submental fat and your personal treatment goals.xi

The most common side effects observed in clinical studies are swelling, bruising, pain, numbness, redness and formation of areas of hardness in the treatment area.xii In clinical trials, the incidence and severity of most side effects were mild to moderate and decreased with subsequent BELKYRA™ treatments.xiii For most people, downtime was minimal and occurred most commonly after the first treatment session.xiv BELKYRA™ should only be administered by a licensed medical aesthetic physician that has been specially trained in the use of the product.

BELKYRATM has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which 1,600 have been treated with BELKYRATM.xv

To learn more about BELKYRA™, consumers can visit  

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world’s third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan’s website at


i Belkyra Product Monograph: July 2015. p. 3
ii Belkyra Product Monograph: July 2015, p. 12
iii American Society for Dermatologic Surgery 2014 Consumer Survey on Cosmetic Dermatologic Procedures (N=8,315); Exact survey language was, “How bothered are you by excess fat under the chin/neck?”
iv DeFatta R, Ducic Y. Liposuction of the face and neck. Operative Techniques in Otolaryngology. 2007; 18:261-266.
v Swift. A, Remington. K, BeautiPHIcation: A Global Approach to Facial Beauty. Clin Plastic Surgery 38 (2011) 347-377 p. 4
vi American Society for Dermatologic Surgery 2014 Consumer Survey on Cosmetic Dermatologic Procedures (N=8,315); Exact survey language was, “How bothered are you by excess fat under the chin/neck?”
vii Swift. A, Remington. K, BeautiPHIcation: A Global Approach to Facial Beauty. Clin Plastic Surgery 38 (2011) 347-377p. 4
viii Belkyra Product Monograph: July 2015, Figure 4, p. 17
ix Data on file: Kybella™ Package Insert, April 2015
x Belkyra Product Monograph: July 2015, p. 21
xi Belkyra Product Monograph: July 2015, p. 21
xii Belkyra Product Monograph: July 2015, p. 21
xiii Data on File: NDA Section7.5.2, page 81
xiv Data on File: NDA Section7.5.2, page 81
xv Data on File: NDA Section 5.1, page 18

SOURCE Allergan

For further information: Environics Communications, Sheba Zaidi or Aliya Darvesh, 416-969-2652 / 416-969-2777, /

Email a friendEmail a friend PrintPrint FeedbackFeedback  |   Bookmark and Share